Cassava Sciences, Inc.

NasdaqCM SAVA

Cassava Sciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 53.48

Cassava Sciences, Inc. Price to Sales Ratio (P/S) is 53.48 on January 14, 2025, a -88.47% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Cassava Sciences, Inc. 52-week high Price to Sales Ratio (P/S) is 692.21 on August 05, 2024, which is 1,194.36% above the current Price to Sales Ratio (P/S).
Cassava Sciences, Inc. 52-week low Price to Sales Ratio (P/S) is 46.92 on December 19, 2024, which is -12.26% below the current Price to Sales Ratio (P/S).
Cassava Sciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 387.25.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: SAVA

Cassava Sciences, Inc.

CEO	Mr. Richard Jon Barry
IPO Date	July 14, 2000
Location	United States
Headquarters	7801 North Capital of Texas Highway
Employees	29
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key trends

Past 5 years